



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/557, 9/22 // (A61K 31/557 A61K 31/54, 31/195)	A1	(11) International Publication Number: WO 91/16895 (43) International Publication Date: 14 November 1991 (14.11.91)
(21) International Application Number: PCT/US91/02980 (22) International Filing Date: 1 May 1991 (01.05.91) (30) Priority data: 518,353 3 May 1990 (03.05.90) US (71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; P.O. Box 5110, Chicago, IL 60680-5110 (US). (72) Inventors; and (75) Inventors/Applicants (for US only) : GIMET, René, Antoine [FR/FR]; 1713, route de Cannes, F-06560 Valbonne (FR). JINOT, Jean-Charles [FR/FR]; 23, avenue des Mimosas, F-06800 Cagnes-sur-Mer (FR). MAGNET, Christian [FR/FR]; 27, rue de la Bourdillière, F-37390 Chateaux-sur-Choisille (FR). MAROTEAUX, Isabelle [FR/FR]; 1133, route de Saint-Jean, F-06600 Antibes (FR). NEVOUX, Françoise, M. [FR/US]; 1016 Austin, Evanston, IL 60202 (US). SCOYER, Roger [BE/BE]; 10, rue du Cimetière, B-5979 Jemeppe-sur-Sambre (BE). STRUTHERS, Barbara, J. [US/US]; 1706 Garand Drive, Deerfield, IL 60015 (US).		(74) Agents: WILLIAMS, Roger, A. et al.; G.D. Searle & Co., P.O. Box 5110, Chicago, IL 60680-5110 (US). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHARMACEUTICAL COMPOSITION (57) Abstract A pharmaceutical composition including a core (18) of an NSAID selected from diclofenac and piroxicam which core is surrounded by a mantle coating (22) of a prostaglandin, wherein an intermediate coating (20) can be present between the NSAID core and prostaglandin mantle coating.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

PHARMACEUTICAL COMPOSITION

Background of the Invention

The invention herein is directed to a pharmaceutical composition which consists of a core/mantle tablet having an inner core and an outer mantle coating surrounding the inner core. The inner core consists of an NSAID selected from diclofenac and piroxicam. The mantle coating consists of a prostaglandin such as will be described hereinafter in more detail.

Nonsteroidal anti-inflammatory drugs (NSAIDs) comprise a class of drugs which have long been recognized as having high therapeutic value especially for the treatment of inflammatory conditions such as exhibited in inflammatory diseases like osteoarthritis (OA) and rheumatoid arthritis (RA). While the NSAIDs present a beneficial therapeutic value they also exhibit undesirable side effects. An especially undesirable side effect of the administration of NSAIDs is the ulcerogenic effects generally associated

2

with chronic use. The chronic use of NSAIDs, the use of high dosages of NSAIDs and the use of NSAIDs by the elderly can lead to NSAID induced ulcers. NSAID induced ulcers in the stomach can be dangerous. Such ulcers generally exhibit few or no symptoms and may cause dangerous bleeding when undetected. In some instances, bleeding ulcers can prove fatal. The United States Food and Drug Administration requires a class warning for all NSAIDs, which states: Serious gastrointestinal toxicity such as bleeding, ulceration, and perforation can occur at any time, with or without warning symptoms, in patients treated chronically with NSAID therapy.

Certain prostaglandins have been shown to prevent NSAID induced ulcers. Acceptable prostaglandin compounds for the invention herein and their preparation are described in U.S. Patents 3,965,143, 4,060,691, 4,271,314 and 4,683,328. The prostaglandin compound commercially available under the USAN (United States Adopted Name) name misoprostol is a pharmaceutically acceptable prostaglandin which has been accepted for use in the treatment of NSAID induced ulcers in many countries, including the United States. Misoprostol is commercially available by prescription in such countries.


3

While prostaglandins are beneficial compounds and have found therapeutic usage, prostaglandins are generally considered highly unstable. Therefore, it is desirable to find prostaglandins with the desired anti-ulcerogenic properties and which can be stabilized or provided in stabilized formulations especially with respect to contemplated oral methods of delivery.



It would be desirable to provide a pharmaceutical composition which would exhibit the beneficial properties of an NSAID and which composition would exhibit the beneficial properties of a prostaglandin for countering (by inhibiting, reducing or preventing) the ulcerogenic side effects attendant to NSAID administration.

Summary of the Invention

The invention herein is directed to a pharmaceutical composition comprising a core consisting of an NSAID selected from diclofenac and piroxicam and a mantle coating consisting of a prostaglandin surrounding the core. The prostaglandin preferably is an orally available prostaglandin. Acceptable prostaglandins for use herein include prostaglandins having the following structure



4



wherein R represents hydrogen or lower alkyl having 1 to 6 carbon atoms; R_1 represents hydrogen, vinyl or lower alkyl having 1 to 4 carbon atoms and the wavy line represents R or S stereochemistry; R_2 , R_3 , and R_4 are hydrogen or lower alkyl having 1 to 4 carbon atoms or R_2 and R_3 together with carbon Y form a cycloalkenyl having 4 to 6 carbon atoms or R_3 and R_4 together with carbons X and Y form a cycloalkenyl having 4 to 6 carbons and wherein the X-Y bond can be saturated or unsaturated.

Another embodiment of the invention herein is a pharmaceutical composition wherein a coating is provided which is an intermediate coating that surrounds the core but lies underneath the mantle coating. Such an intermediate coating can be an additional coating for

5

preventing contact between the NSAID and the prostaglandin to thereby inhibit any deleterious or otherwise non-beneficial interaction of the NSAID and prostaglandin such as degradation of the prostaglandin. Such an intermediate coating can be an enteric coating which aids in reducing the likelihood of the NSAID dissolving in the stomach and thereby directly exposing the stomach to the NSAID.

A preferred pharmaceutical composition herein has a structure wherein the core comprises the NSAID, diclofenac in a therapeutic amount such as from 25 to 75 milligrams (mg) and a mantle coating surrounding the core comprising the prostaglandin misoprostol in a therapeutic amount of about 100 to 200 micrograms (mcg).

Another embodiment of the invention herein is a pharmaceutical composition including an NSAID core, an undercoating on the core surface of hydroxypropyl methylcellulose (HPMC), an enteric coating, an overcoat on the enteric coating of HPMC, and a mantle coating of the prostaglandin.

The invention herein will be more fully understood with regard to the following brief description of the accompanying drawings and the following detailed description.

6

Brief Description of the Drawings


Figure 1 is a schematic representation of a tableted pharmaceutical composition herein illustrating the core/mantle structure;

Figure 2 is a schematic representation of another embodiment of a tableted pharmaceutical composition herein; and

Figure 3 is a schematic representation of still another embodiment of a tableted pharmaceutical composition herein.

Detailed Description of the Invention

The invention herein is directed to a pharmaceutical composition which is a core/mantle tablet consisting of a core of a nonsteroidal anti-inflammatory drug (NSAID) selected from diclofenac and piroxicam. Surrounding the core is a mantle coating which consists of a prostaglandin of the structure



7

wherein R represents hydrogen or lower alkyl having 1 to 6 carbon atoms; R_1 represents hydrogen, vinyl or lower alkyl having 1 to 4 carbon atoms and the wavy line represents R or S stereochemistry; R_2 , R_3 , and R_4 are hydrogen or lower alkyl having 1 to 4 carbon atoms or R_2 and R_3 together with carbon Y form a cycloalkenyl having 4 to 6 carbon atoms or R_3 and R_4 together with carbons X and Y form a cycloalkenyl having 4 to 6 carbons and wherein the X-Y bond can be saturated or unsaturated.

The pharmaceutical composition herein can be described with regard to the accompanying drawings wherein Figures 1, 2 and 3 represent separate embodiments of the tableted composition herein.

The pharmaceutical composition will first be described with regard to the embodiment shown in Figure 1. Figure 1 represents a schematic illustration of a pharmaceutical composition herein. The pharmaceutical composition consists of a core/mantle tablet 10 which can have any geometric shape. For example, a bi-convex tablet (general pill shape) can be used which has a generally oval cross section taken along a vertical cross section and a circular cross section taken along a horizontal cross section. A bi-convex tablet can include a straight side wall (cylindrical) portion although such a tablet is not

8

shown in the drawings herein. For ase of discussion herein a vertical cross sectional view providing an oval cross section will be used to describe the invention herein although it is understood that other shapes can be used without departing from the intended scope of the invention. A generally oval cross-section is shown in Figure 1. The tablet 10 includes an inner core 12 which is comprised of an NSAID that is compatible with the prostaglandin as will be described in further detail hereinafter. The inner core 12 can consist of the NSAID, diclofenac or piroxicam or the pharmaceutically acceptable salts of such NSAIDs. The inner core 12 can be formulated by compressing the diclofenac or piroxicam in any suitable tableting equipment using compression tableting techniques well known in the art.

For a tablet wherein the inner core comprises diclofenac it has been found that the diclofenac can be present as diclofenac sodium. The diclofenac can be present in any therapeutically acceptable amount. For normal pharmaceutically acceptable dosing of diclofenac, diclofenac is administered in a therapeutic dosing range using tablets containing from 25 mg to 75 mg per tablet. The Physicians' Desk Reference (PDR), 44th Edition, states that the recommended dosage for treating osteoarthritis is

9

100 to 150 mg per day in divided doses. For treating rheumatoid arthritis the recommended dosage is 150 to 200 mg per day in divided doses. For ankylosing spondylitis the recommended dosage is 100 to 125 mg per day in divided doses. The inner core for the pharmaceutical composition herein can contain an amount from 25 to 75 mg of diclofenac and preferably a dosage of 50 mg. Various excipients such as binders, bulking agents, lubricants, fillers and the like, can be combined with the diclofenac in the core as is well known in the pharmaceutical art. Excipients used are selected from those which do not exhibit a destabilizing effect on either the diclofenac or prostaglandin.


If the inner core is piroxicam, the piroxicam can be present in a therapeutically acceptable amount. Currently, commercially available piroxicam tablets contain either 10 mg or 20 mg of piroxicam. The PDR, 44th Edition, recommends that piroxicam be administered in a single daily dose of 20 mg for rheumatoid arthritis and osteoarthritis. For the pharmaceutical composition herein the inner core can contain from 10 to 20 mg of piroxicam. Various excipients can be used in constructing a piroxicam core which excipients do not exhibit a destabilizing effect on either the piroxicam or the prostaglandin.

10


A mantle coating 14 surrounds the inner NSAID core and encapsulates the NSAID. The mantle coating includes a prostaglandin and more preferably an orally available prostaglandin.

The terms "prostaglandin" and/or its accepted acronym "PG" or, as more appropriately for the E-series prostaglandins, "PGE," are used herein to refer to naturally occurring or man-made E-series prostaglandins and their analogs and derivatives.

It has been found herein that acceptable prostaglandins include E₁ prostaglandins represented by the following Formula I:




E₂ prostaglandins represented by the following Formula II:



11

and E₃ prostaglandins represented by the following
Formula III:




wherein R represents hydrogen or lower alkyl having 1 to 6 carbon atoms, R₁ represents hydrogen, vinyl or lower alkyl having 1 to 4 carbon atoms and the wavy line represents R or S stereochemistry; R₂, R₃, and R₄ are hydrogen or lower alkyl having 1 to 4 carbon atoms or R₂ and R₃ together with carbon Y form a cycloalkenyl having 4 to 6 carbon atoms or R₃ or R₄ together with carbons X and Y form a cycloalkenyl having 4 to 6 carbon and wherein the X-Y bond can be saturated or unsaturated.


By lower alkyl is meant straight or branched chain alkyl such as methyl, ethyl, propyl, isopropyl, butyl, secondary butyl or tertiary butyl, pentyl, or hexyl with the indicated limitation of the number of carbon atoms. The bond between carbon X and carbon Y can be saturated or unsaturated.

12


It has been found herein that acceptable prostaglandins include misoprostol represented by the following Formula :



the prostaglandin enisoprost, (+)methyl 11 α ,16-dihydroxy-16-methyl-9-oxoprosto-4Z,13E-diene-1-oate, represented by the following Formula:



and the prostaglandin methyl 7-[2B-[6-(1-cyclopenten-1-yl)-4-hydroxy-4-methyl-1E,5E-hexadienyl]-3 α -hydroxy-5-oxo-1R,1 α -cyclopentyl]-4Z-heptenoate represented by the following Formula:



13

With regard to the illustrated structures, the dashed line indicates the grouping being behind the plane of the paper and the solid, blackened triangular shape indicates that the group is in front of the plane of the paper.

The prostaglandins useful in the composition of the invention herein can be prepared by known reaction schemes such as by the methods taught in U.S. Patents 3,965,143; 4,271,314; and 4,683,328. The individual isomers can be obtained by chromatographic separation.

When the prostaglandin is misoprostol, (+)methyl 11 α ,16-dihydroxy-16-methyl-9-oxoprost-13E-en-1-oate, the misoprostol is present in an amount from about 50 to about 500 mcg and preferably from about 100 to about 200 mcg.

A second embodiment of the composition is shown in Figure 2. In Figure 2 a tablet 16 is schematically illustrated in cross section. The tablet 16 includes an inner core 18 of an NSAID diclofenac, piroxicam or their salts such as disclosed with regard to the core 12 of Figure 1. Surrounding the core 18 is an enteric coating 20. The enteric coating 20 can be formulated from any suitable enteric coating material, many of which are known to those skilled in the art and many of which are employed for coating commercially available NSAID's. The coating 20 aids in segregating the NSAID from the prostaglandin

14

and in directing the dissolution of the NSAID core in the lower G.I. tract as opposed to the stomach. The coating 20 can aid in the prevention of degradation of the prostaglandin by the presence of the NSAID. The enteric coating can be coated onto the inner core using standard coating techniques. For example, aqueous or solvent coating techniques can be used to apply the enteric coating to the inner core. Surrounding the coated inner core is a mantle 22 consisting of a prostaglandin as described with regard to mantle 14 in the composition embodiment represented in Figure 1.

A third embodiment of the composition is shown in Figure 3. In Figure 3 a tablet 24 is illustrated in cross section. The tablet 24 consists of an inner core 26 comprising an NSAID or its salt as disclosed with regard to the core 12 of Figure 1. Surrounding the core 26 is an undercoat 28 which can provide a surface for the enteric coat which undercoat can have a greater affinity for the enteric coat than the core alone. The coating 28 can be any suitable coating material and preferably is HPMC in an amount about two percent (2%) by weight of the core.

15

An aqueous enteric coating 30 can be used to segregate the NSAID from the prostaglandin and to aid in controlling release of the NSAID. The undercoat 28 prevents water which can be present in the aqueous enteric coat 30 from penetrating into the NSAID core to cause any undesirable effects on the NSAID which might be caused by water. The enteric coating 30 can aid in the prevention of degradation of the prostaglandin by the presence of the NSAID as well as direct delivery of the NSAID in the lower G.I. tract rather than the stomach. Any aqueous enteric coating can be used and the enteric coating can be coated onto the inner core using standard coating techniques as described with regard to the embodiment shown in Figure 2.

An overcoat 32 is coated over the enteric coat 30. The overcoat 32 can provide an intermediate coating providing affinity between the enteric coat and mantle. The overcoat can be any suitable material, preferably the overcoat is HPMC in an amount about three percent (3%) by weight of the core. The overcoat 32 prevents water which can be present in the aqueous enteric coating from passing into the prostaglandin mantle. Further, the overcoat can aid in maintaining the integrity of the enteric coating during the compression coating step as the mantle is formed on the tablet.

16

A mantle 34 consisting of a prostaglandin as described with regard to mantle 14 in the composition embodiment shown in Figure 1 is coated, such as by compression coating, over the overcoat 32.

It has been found herein that an especially preferred composition is the use of misoprostol as the prostaglandin in the mantle and the use of diclofenac in the inner core.

The invention will be further described with regard to the following examples.

17

Example 1

A pharmaceutical tablet composition was prepared consisting of a diclofenac sodium central core and a misoprostol mantle. The tablet had the following composition.

Core	Unit Formula (mg)
diclofenac sodium	50.0
lactose (monohydrate)	13.0
microcrystalline cellulose	12.9
cornstarch	8.4
povidone K-30	4.8
magnesium stearate	0.9
purified water	
Mantle	
misoprostol:HPMC dispersion (1:100)	
misoprostol	0.2
hydroxypropyl methylcellulose (HPMC)	20.0
crospovidone	10.0
colloidal silicon dioxide	0.5
hydrogenated castor oil	1.0
microcrystalline cellulose	233.3

18

Example 2

A pharmaceutical tablet composition was prepared consisting of a diclofenac sodium central core, an enteric coating and a misoprostol mantle. The tablet had the following composition.

Core	Unit Formula (mg)
diclofenac sodium	50.0
lactose (monohydrate)	13.0
microcrystalline cellulose	12.9
cornstarch	8.4
povidone K-30	4.8
magnesium stearate	0.9
purified water	
Core coating	
cellulose acetate phthalate	5.4
diethyl phthalate	1.5
Mantle	
misoprostol:HPMC dispersion (1:100)	
misoprostol	0.2
hydroxypropyl methylcellulose	20.0
crospovidone	10.0
colloidal silicon dioxide	0.5
hydrogenated castor oil	1.0
microcrystallin cellulose	233.3

19

Example 3

A pharmaceutical tablet composition was prepared consisting of a diclofenac sodium central core, an aqueous enteric coating, an overcoat and a misoprostol mantle. The tablet had the following composition.

Core	Unit Formula (mg)
diclofenac sodium	50.0
lactose (monohydrate)	13.0
microcrystalline cellulose	12.9
cornstarch	8.4
povidone K-30	4.8
magnesium stearate	0.9
Enteric coating (aqueous)	
methacrylic acid	
copolymer type C	3.68
sodium hydroxide	0.049
talcum	1.84
triethyl citrate	0.37

20

Overcoating

HPMC	2.72
polyethylene glycol (PEG 400)	0.054

Mantle

misoprostol:HPMC dispersion (1:100)	
misoprostol	0.2
hydroxypropyl methylcellulose	20.0
crospovidone	10.0
colloidal silicon dioxide	0.5
hydrogenated castor oil	1.0
microcrystalline cellulose	233.3

21

Example 4

A pharmaceutical tablet composition was prepared consisting of a diclofenac sodium central core, an undercoat, an enteric coating, and a misoprostol mantle. The tablet had the following composition.

Core	Unit Formula (mg)
diclofenac sodium	50.0
lactose (monohydrate)	13.0
microcrystalline cellulose	12.9
cornstarch	8.4
povidone K-30	4.8
magnesium stearate	0.9
Undercoat	
HPMC	1.84
PEG 400	0.037
Enteric coating (aqueous)	
methacrylic acid	
copolymer type C	3.68
sodium hydroxide	0.049
talcum	1.84
triethyl citrate	0.37

22

Mantle

misoprostol:HPMC dispersion (1:100)

misoprostol	0.2
hydroxypropyl methylcellulose	20.0
crospovidone	10.0
colloidal silicon dioxide	0.5
hydrogenated castor oil	1.0
microcrystalline cellulose	233.3

23

Example 5

A pharmaceutical tablet composition was prepared consisting of a diclofenac sodium central core, an undercoat, an enteric coating, an overcoat and a misoprostol mantle. The tablet had the following composition.

Core	Unit Formula (mg)
diclofenac sodium	50.0
lactose (monohydrate)	13.0
microcrystalline cellulose	12.9
cornstarch	8.4
povidone K-30	4.8
magnesium stearate	0.9
Undercoat	
HPMC	1.84
PEG 400	0.037
Enteric coating (aqueous)	
methacrylic acid	
copolymer type C	3.68
sodium hydroxide	0.049
talcum	1.84
triethyl citrate	0.37

24

Overcoating

HPMC	2.72
PEG 400	0.054

Mantle

misoprostol:HPMC dispersion (1:100)	
misoprostol	0.2
hydroxypropyl methylcellulose	20.0
crospovidone	10.0
colloidal silicon dioxide	0.5
hydrogenated castor oil	1.0
microcrystalline cellulose	233.3

25

Example 6

A pharmaceutical tablet composition was prepared consisting of a diclofenac sodium central core, an enteric coating, an overcoat and a misoprostol mantle. The tablet had the following composition.

Core	Unit Formula (mg)
diclofenac sodium	50.0
lactose (monohydrate)	13.0
microcrystalline cellulose	12.9
cornstarch	8.4
povidone K-30	4.8
magnesium stearate	0.9
Enteric coating (aqueous)	
methacrylic acid	
copolymer type C	3.68
talcum	1.84
triethyl citrate	0.37

26

Overcoating

HPMC	2.72
PEG 400	0.054

Mantle

misoprostol:HPMC dispersion (1:100)

misoprostol	0.2
-------------	-----

hydroxypropyl methylcellulose	20.0
-------------------------------	------

crospovidone	10.0
--------------	------

colloidal silicon dioxide	0.5
---------------------------	-----

hydrogenated castor oil	1.0
-------------------------	-----

microcrystalline cellulose	233.3
----------------------------	-------

27

Example 7

A pharmaceutical tablet composition was prepared consisting of a diclofenac sodium central core, an enteric coating, an overcoat and a misoprostol mantle. The tablet had the following composition.

Core	Unit Formula (mg)
diclofenac sodium	50.0
lactose (monohydrate)	13.0
microcrystalline cellulose	12.9
cornstarch	8.4
povidone K-30	4.8
magnesium stearate	0.9
Enteric coating (aqueous)	
Aquateric	6.53
polysorbate 80	0.13
diethyl phthalate (DEP)	1.96

28

Overcoating

HPMC	2.72
PEG 400	0.054

Mantle

misoprostol:HPMC dispersion (1:100)	
misoprostol	0.2
hydroxypropyl methylcellulose	20.0
crospovidone	10.0
colloidal silicon dioxide	0.5
hydrogenated castor oil	1.0
microcrystalline cellulose	233.3

29

Example 8

A pharmaceutical tablet composition was prepared consisting of a diclofenac sodium central core, an undercoat, an enteric coating, and a misoprostol mantle. The tablet had the following composition.

Core	Unit Formula (mg)
diclofenac sodium	50.0
lactose (monohydrate)	13.0
microcrystalline cellulose	12.9
cornstarch	8.4
povidone K-30	4.8
magnesium stearate	0.9
Undercoat	
HPMC	1.84
PEG 400	0.037
Enteric coating (aqueous)	
Aquateric	6.56
polysorbate 80	0.13
diethyl phthalate (DEP)	1.97

30

Mantle

misoprostol:HPMC dispersion (1:100)

misoprostol	0.2
-------------	-----

hydroxypropyl methylcellulose	20.0
-------------------------------	------

crospovidone	10.0
--------------	------

colloidal silicon dioxide	0.5
---------------------------	-----

hydrogenated castor oil	1.0
-------------------------	-----

microcrystalline cellulose	233.3
----------------------------	-------

31

Example 9

A pharmaceutical tablet composition was prepared consisting of a diclofenac sodium central core, an undercoat, an enteric coating, an overcoat and a misoprostol mantle. The tablet had the following composition.

Core	Unit Formula (mg)
diclofenac sodium	50.0
lactose (monohydrate)	13.0
microcrystalline cellulose	12.9
cornstarch	8.4
povidone K-30	4.8
magnesium stearate	0.9
Undercoat	
HPMC	1.84
PEG 400	0.037
Enteric coating (aqueous)	
Aquateric	6.56
polysorbate 80	0.13
diethyl phthalate (DEP)	1.97

32

Overcoating

HPMC	2.70
PEG 400	0.054

Mantle

misoprostol:HPMC dispersion (1:100)	
misoprostol	0.2
hydroxypropyl methylcellulose	20.0
crospovidone	10.0
colloidal silicon dioxide	0.5
hydrogenated castor oil	1.0
microcrystalline cellulose	233.3

The composition that is the invention herein provides an ease of delivery of an NSAID for its therapeutic value such as the alleviation of inflammation in a system which limits the undesirable side affects of ulcerogenesis associated with such NSAID therapy. That is, the composition herein consisting of essentially a core/mantle tablet provides a prostaglandin along with the NSAID whereby the prostaglandin can be administered for its beneficial therapeutic value in preventing and or inhibiting the incidence of NSAID induced ulcers.


A particularly beneficial aspect of the invention herein is that the combination of the two components in a core/mantle tablet assures compliance with the therapeutic regimen of the two active components. That is, a co-administration of the active components (NSAID and prostaglandin) separately can be difficult to achieve and can be difficult for a patient to faithfully follow. By placing the two active components in the same tablet or composition, adherence to the therapeutic regimen is controlled as the administration of the tablet containing the NSAID assures compliance of the administration of the prostaglandin also present in the tablet.

The composition herein is especially utile as the composition herein exhibits a stability for the prostaglandin and the NSAID.


34

Claims

1. A pharmaceutical composition comprising:
 - a. a core consisting of an NSAID selected from diclofenac and piroxicam; and
 - b. a mantle coating surrounding the core consisting of a prostaglandin of the structural formula




2. A pharmaceutical composition as recited in Claim 1 wherein the prostaglandin comprises a prostaglandin of the structural formula



35


3. A pharmaceutical composition as recited in Claim 2 wherein the prostaglandin comprises misoprostol.

4. A pharmaceutical composition as recited in Claim 1 wherein the prostaglandin comprises the structural formula



5. A pharmaceutical composition as recited in Claim 4 wherein the prostaglandin comprises enisoprost.

6. A pharmaceutical composition as recited in Claim 1 wherein the prostaglandin comprises a structural formula



7. A pharmaceutical composition as recited in Claim 1 wherein the NSAID comprises diclofenac.

8. A pharmaceutical composition as recited in Claim 1 wherein the NSAID comprises piroxicam.




36

9. A pharmaceutical composition as recited in Claim 1 further comprising an intermediate coating surrounding the core.
10. A pharmaceutical composition as recited in Claim 9 wherein the intermediate coating comprises an enteric coating.
11. A pharmaceutical composition as recited in Claim 1 wherein the prostaglandin mantle coating comprises a stabilized prostaglandin formulation.
12. A pharmaceutical composition as recited in Claim 1 wherein the NSAID comprises diclofenac from about 25 to 75 mg and the mantle coating comprises a stabilized prostaglandin formulation containing an amount of about 200 mcg of misoprostol.

37

13. A method of treating inflammation comprising administering to a patient in need of such treatment, a therapeutically effective amount of a composition according to Claim 1.


1/1



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/02980

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl.5	A 61 K 31:557	A 61 K 9/22 //(A 61 K 31:557
A 61 K 31:54	A 61 K 31:195)	
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl.5	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	GB,A,2135881 (FARMITALIA CARLO ERBA SpA) 12 September 1984, see page 12, line 1 - page 16, line 48; claims 1-29 -----	1-12
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
26-08-1991	08. 10. 91	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	 Nurla TORIBIO	

Form PCT/ISA/210 (second sheet) (January 1985)

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim numbers 13 because they relate to subject matter not required to be searched by this Authority, namely:
see PCT-Rule 39.1(iv)
2. ☐ Claim numbers because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:
3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6 4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; It is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest
- ☐ No protest accompanied the payment of additional search fees

US 9102980
SA 47633

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

FILED() F()RM 10479

BNSDOCID: <WO 9116895A1>

